ACR 2017 Conference Correspondent

The phase 3 TARGET study demonstrated that sarilumab (150 or 200 mg subcutaneously every 2 weeks [q2w]) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) achieved clinical responses in terms of rheumatoid arthritis (RA) signs and symptoms and physical function compared with placebo in adults with active, moderate-to-severe RA who were intolerant of, or showed inadequate response to, tumor necrosis factor (TNF) inhibitors.

This post hoc analysis examined efficacy and safety outcomes from patients who completed the ASCERTAIN trial and switched to subcutaneous sarilumab 200 mg q2w.

The current study examines whether high cTnI also predicts incident long-term cardiovascular (CV) events and optimizes CV risk stratification in the Prospective Evaluation of Lateral Coronary Atherosclerosis in RA (PROTECT-RA) trial after 5 years of follow-up.

The phase 3 SIRROUND-D trial demonstrated that sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, resulted in significant reduction in rheumatoid arthritis (RA) signs and symptoms, and inhibited radiographic progression at week 52 compared with placebo in patients with active RA despite disease-modifying antirheumatic drug (DMARD) treatment.

Sarilumab, a human monoclonal antibody that inhibits interleukin (IL)-6–mediated signaling by blocking IL-6 receptor alpha, is currently approved for the treatment of moderately to severely active rheumatoid arthritis (RA).

The efficacy and safety of sarilu­mab, a human monoclonal antibody blocking the interleukin-6 receptor alpha, were evaluated for treatment of rheumatoid arthritis (RA) in 3 clinical trials, including the MOBILITY trial.

This analysis of the MOBILITY and TARGET studies showed that patients treated with sarilumab achieved responses as early as week 4, and that ongoing sarilumab treatment resulted in achievement of remission or LDA through week 24, with additional increases seen through week 52 (MOBILITY).

Tofacitinib, an oral Janus kinase inhibitor, is approved for the treatment of rheumatoid arthritis (RA).

The current study reported on updated integrated safety data from 8 randomized trials that further described the safety profile for up to 5.5 years of baricitinib in adult patients with moderately to severely active RA.

Page 2 of 2
Results 11 - 19 of 19
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology